Total Valuation
Regencell Bioscience has a market cap or net worth of $3.64B. The enterprise value is $10.00T>.
Market Cap$3.64B
Enterprise Value$10.00T>
Share Statistics
Regencell Bioscience has 495,884,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding495,884,370
Owned by Insiders―
Owned by Institutions0.09%
Financial Efficiency
Regencell Bioscience’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -85.92%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-85.92%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee0.00
Profits Per Employee-1.17M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Regencell Bioscience is ―. Regencell Bioscience’s PEG ratio is -1.12.
PE Ratio―
PS Ratio0.00
PB Ratio225.64
Price to FCF-391.41
Price to Operating Cash Flow-472.49
PEG Ratio-1.12
Income Statement
In the last 12 months, Regencell Bioscience had revenue of 0.00 and earned -11.70M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-404.54K
Operating Income-11.72M
Pretax Income-11.70M
Net Income-11.70M
EBITDA-11.32M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -7.70M and capital expenditures -2.00, giving a free cash flow of -7.70M billion.
Operating Cash Flow-7.70M
Free Cash Flow-7.70M
Free Cash Flow per Share-0.02
Dividends & Yields
Regencell Bioscience pays an annual dividend of $0.22, resulting in a dividend yield of 318.47%
Dividend Per Share$0.22
Dividend Yield318.47%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.04
52-Week Price Change-59.14%
50-Day Moving Average5.96
200-Day Moving Average18.87
Relative Strength Index (RSI)64.37
Average Volume (3m)172.28K
Important Dates
Regencell Bioscience upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Regencell Bioscience as a current ratio of 10.77, with Debt / Equity ratio of 2.22%
Current Ratio10.77
Quick Ratio10.77
Debt to Market Cap<0.01
Net Debt to EBITDA1.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Regencell Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Regencell Bioscience EV to EBITDA ratio is -264.86, with an EV/FCF ratio of -389.61.
EV to Sales0.00
EV to EBITDA-264.86
EV to Free Cash Flow-389.61
EV to Operating Cash Flow-389.61
Balance Sheet
Regencell Bioscience has $14.19M in cash and marketable securities with $295.81K in debt, giving a net cash position of $13.90M billion.
Cash & Marketable Securities$14.19M
Total Debt$295.81K
Net Cash$13.90M
Net Cash Per Share$0.03
Tangible Book Value Per Share$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Regencell Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-227.78%